MedPath

Ondansetron

These highlights do not include all the information needed to use ONDANSETRON TABLETS and ONDANSETRON ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for ONDANSETRON TABLETS and ONDANSETRON ORALLY DISINTEGRATING TABLETS. ONDANSETRON tablets, for oral useONDANSETRON orally disintegrating tabletsInitial U.S. Approval: 1991

Approved
Approval ID

92a8467d-aece-45ae-b8c8-21988901ba5f

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jul 11, 2017

Manufacturers
FDA

Unit Dose Services

DUNS: 831995316

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Ondansetron

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code50436-0134
Application NumberANDA078152
Product Classification
M
Marketing Category
C73584
G
Generic Name
Ondansetron
Product Specifications
Route of AdministrationORAL
Effective DateNovember 4, 2016
FDA Product Classification

INGREDIENTS (7)

ASPARTAMEInactive
Code: Z0H242BBR1
Classification: IACT
SILICON DIOXIDEInactive
Code: ETJ7Z6XBU4
Classification: IACT
CROSPOVIDONE (15 MPA.S AT 5%)Inactive
Code: 68401960MK
Classification: IACT
MAGNESIUM STEARATEInactive
Code: 70097M6I30
Classification: IACT
SODIUM STEARYL FUMARATEInactive
Code: 7CV7WJK4UI
Classification: IACT
ONDANSETRONActive
Quantity: 4 mg in 1 1
Code: 4AF302ESOS
Classification: ACTIB
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Ondansetron - FDA Drug Approval Details